FOLH1 and neoplasm: These include CC-1 [26], TNB-585 [27], CCW702 [28], and AMG 160 [29] with selection criteria not based on PSMA and effector T-cell levels, that likely results in the inclusion of patients with either immunologically “cold” or PSMA negative tumours.